A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This was a Phase 2a trial to investigate the safety and biological activity of the RIX-2
Regimen in patients with untreated, resectable squamous cell cancer of the head and neck
(HNSCC).